Table of Content

1. PREFACE
1.1. Chapter Overview
1.2. Key Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Contract Manufacturing
3.3. Commonly Outsourced Operations in Biopharmaceutical Industry
3.3.1. Aseptic Fill Finish Operations
3.4. Basic Guidelines for Selecting a Fill Finish Service Provider
3.5. Advantages of Outsourcing Fill Finish Operations
3.6. Risks and Challenges Associated with Outsourcing Fill Finish Operations
3.7. Concluding Remarks

4. ASEPTIC FILL FINISH SERVICE PROVIDERS LANDSCAPE
4.1. Chapter Overview
4.2. Aseptic Fill / Finish: Service Providers Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Type of Molecule(s)
4.2.5. Analysis by Type of Packaging Container(s) Offered

5. BIOLOGICS FILL FINISH SERVICE PROVIDERS LANDSCAPE
5.1. Chapter Overview
5.2. Biologics Fill Finish: Service Providers Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Location of Fill Finish Facilities
5.2.5. Analysis by Type of Packaging Container(s) Offered
5.2.6. Analysis by Type of Drug Product(s) Involved
5.2.7. Analysis by Scale of Operation
5.2.8. Analysis by Additional Drug Product-related Services Offered
5.2.9. Information on Fill Finish Capacity

6. SMALL MOLECULE FILL FINISH SERVICE PROVIDERS LANDSCAPE
6.1. Chapter Overview
6.2. Small Molecule Fill Finish: Service Providers Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Location of Headquarters
6.2.4. Analysis by Location of Fill Finish Facilities
6.2.5. Analysis by Type of Filling Service(s) Offered
6.2.6. Analysis by Type of Finishing Service(s) Offered
6.2.7. Analysis by Type of Packaging Container(s) Offered
6.2.8. Analysis by Scale of Operation
6.2.9. Analysis by Type of Dosage Form(s) Filled
6.2.10. Analysis by Type of Process(es)
6.2.11. Information on Fill Finish Capacity

7. COMPANY PROFILES: ASEPTIC FILL / FINISH SERVICE PROVIDERS IN NORTH AMERICA
7.1. Chapter Overview
7.2. Companies Offering Aseptic Fill Finish Services for Biologics
7.2.1. AbbVie Contract Manufacturing
7.2.1.1. Company Snapshot
7.2.1.2. Financial Information
7.2.1.3. Service Portfolio
7.2.1.4. Fill Finish Services Offered
7.2.1.5. Recent Developments and Future Outlook
7.2.2. BioPharma Solutions
7.2.2.1. Company Snapshot
7.2.2.2. Financial Information
7.2.2.3. Service Portfolio
7.2.2.4. Fill Finish Services Offered
7.2.2.5. Recent Developments and Future Outlook
7.2.3. BioReliance
7.2.3.1. Company Snapshot
7.2.3.2. Financial Information
7.2.3.3. Service Portfolio
7.2.3.4. Fill Finish Services Offered
7.2.3.5. Recent Developments and Future Outlook
7.2.4. Catalent Biologics
7.2.4.1. Company Snapshot
7.2.4.2. Financial Information
7.2.4.3. Service Portfolio
7.2.4.4. Fill Finish Services Offered
7.2.4.5. Recent Developments and Future Outlook
7.2.5. Charles River Laboratories
7.2.5.1. Company Snapshot
7.2.5.2. Financial Information
7.2.5.3. Fill Finish Services Offered
7.2.5.4. Recent Developments and Future Outlook
7.2.6. Patheon
7.2.6.1. Company Snapshot
7.2.6.2. Financial Information
7.2.6.3. Service Portfolio
7.2.6.4. Fill Finish Services Offered
7.2.6.5. Recent Developments and Future Outlook
7.3. Companies Offering Aseptic Fill Finish Services for Small Molecules
7.3.1.1. Pfizer CentreOne
7.3.1.2. Company Snapshot
7.3.1.3. Service Portfolio
7.3.1.4. Fill Finish Services Offered
7.3.1.5. Recent Developments and Future Outlook
7.3.2. Plastikon Healthcare
7.3.2.1. Company Snapshot
7.3.2.2. Service Portfolio
7.3.2.3. Fill Finish Services Offered
7.3.2.4. Recent Developments and Future Outlook
7.3.3. Sharp Services
7.3.3.1. Company Snapshot
7.3.3.2. Service Portfolio
7.3.3.3. Fill Finish Services Offered
7.3.3.4. Recent Developments and Future Outlook

8. COMPANY PROFILES: ASEPTIC FILL FINISH SERVICE PROVIDERS IN EUROPE
8.1. Company Overview
8.2. Companies Offering Aseptic Fill Finish Services for Biologics
8.2.1. Boehringer Ingelheim BioXcellence
8.2.1.1. Company Snapshot
8.2.1.2. Financial Information
8.2.1.3. Service Portfolio
8.2.1.4. Fill Finish Services Offered
8.2.1.5. Recent Developments and Future Outlook
8.2.2. Fareva
8.2.2.1. Company Snapshot
8.2.2.2. Fill Finish Services Offered
8.2.2.3. Recent Developments and Future Outlook
8.2.3. GlaxoSmithKline
8.2.3.1. Company Snapshot
8.2.3.2. Financial Information
8.2.3.3. Fill Finish Services Offered
8.2.3.4. Recent Developments and Future Outlook
8.2.4. Lonza
8.2.4.1. Company Snapshot
8.2.4.2. Financial Information
8.2.4.3. Service Portfolio
8.2.4.4. Fill Finish Services Offered
8.2.4.5. Recent Developments and Future Outlook
8.2.5. Pierre Fabre
8.2.5.1. Company Snapshot
8.2.5.2. Financial Information
8.2.5.3. Service Portfolio
8.2.5.4. Fill Finish Services Offered
8.2.5.5. Recent Developments and Future Outlook
8.2.6. Wacker Biotech
8.2.6.1. Company Snapshot
8.2.6.2. Financial Information
8.2.6.3. Service Portfolio
8.2.6. 4. Fill Finish Services Offered
8.2.6.5. Recent Developments and Future Outlook
8.3. Companies Offering Aseptic Fill Finish Services for Small Molecules
8.3.1. Aenova
8.3.1.1. Company Snapshot
8.3.1.2. Financial Information
8.3.1.3. Service Portfolio
8.3.1.4. Fill Finish Services Offered
8.3.1.5. Recent Developments and Future Outlook
8.3.2. APL
8.3.2.1. Company Snapshot
8.3.2.2. Service Portfolio
8.3.2.3. Fill Finish Services Offered
8.3.2.4. Recent Developments and Future Outlook
8.3.3 CordenPharma
8.3.3.1. Company Snapshot
8.3.3.2. Service Portfolio
8.3.3.3. Fill Finish Services Offered
8.3.3.4. Recent Developments and Future Outlook
8.3.4. Delpharm
8.3.4.1. Company Snapshot
8.3.4.2. Service Portfolio
8.3.4.3. Fill Finish Services Offered
8.3.4.4. Recent Developments and Future Outlook
8.3.5 PiSA Farmaceutica
8.3.5.1. Company Snapshot
8.3.5.2. Service Portfolio
8.3.5.3. Fill Finish Services Offered
8.3.5.4. Recent Developments and Future Outlook
8.4 Companies Offering Aseptic Fill Finish Manufacturing for Biologics and Small Molecules
8.4.1 Fresenius Kabi
8.4.1.1. Company Snapshot
8.4.1.2 Financial Information
8.4.1.3. Service Portfolio
8.4.1.4. Fill Finish Services Offered
8.4.1.5. Recent Developments and Future Outlook
8.4.2 Recipharm
8.4.2.1. Company Snapshot
8.4.2.2. Financial Information
8.4.2.3. Service Portfolio
8.4.2.4. Fill Finish Services Offered
8.4.2.5. Recent Developments and Future Outlook
9. COMPANY PROFILES: ASEPTIC FILL FINISH SERVICE PROVIDERS IN ASIA-PACIFIC
9.1 Company Overview
9.2 Companies Offering Aseptic Fill Finish Services for Biologics
9.2.1 Asymchem
9.2.1.1. Company Snapshot
9.2.1.2. Financial Information
9.2.1.3. Service Portfolio
9.2.1.4. Fill Finish Services Offered
9.2.1.5. Recent Developments and Future Outlook
9.2.2. Samsung Biologics
9.2.2.1. Company Snapshot
9.2.2.2. Financial Information
9.2.2.3. Service Portfolio
9.2.2.4. Fill Finish Services Offered
9.2.2.5. Recent Developments and Future Outlook
9.2.3. Syngene
9.2.3.1. Company Snapshot
9.2.3.2. Financial Information
9.2.3.3. Service Portfolio
9.2.3.4. Fill Finish Services Offered
9.2.3.5. Recent Developments and Future Outlook
9.2.4. Takara Bio
9.2.4.1. Company Snapshot
9.2.4.2. Financial Information
9.2.4.3. Service Portfolio
9.2.4.4. Fill Finish Services Offered
9.2.4.5. Recent Developments and Future Outlook
9.2.5. WuXi Biologics
9.2.5.1. Company Snapshot
9.2.5.2. Financial Information
9.2.5.3. Service Portfolio
9.2.5.4. Fill Finish Services Offered
9.2.5.5. Recent Developments and Future Outlook
9.2.6. Hetero Drugs
9.2.6.1. Company Snapshot
9.2.6.2. Fill Finish Services Offered
9.2.6.3. Recent Developments and Future Outlook
9.2.7. Intas Pharmaceuticals
9.2.7.1. Company Snapshot
9.2.7.2. Fill Finish Services Offered
9.2.7.3. Recent Developments and Future Outlook
9.3. Companies Offering Aseptic Fill Finish Services for Small Molecules
9.3.1. Siegfried
9.3.1.1. Company Snapshot
9.3.1.2. Financial Information
9.3.1.3. Service Portfolio
9.3.1.4. Fill Finish Services Offered
9.3.1.5. Recent Developments and Future Outlook
9.3.2. Wockhardt
9.3.2.1. Company Snapshot
9.3.2.2. Financial Information
9.3.2.3. Service Portfolio
9.3.2.4. Fill Finish Services Offered
9.3.2.5. Recent Developments and Future Outlook

10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Aseptic Fill Finish Service Providers: List of Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Scale of Operation
10.3.4. Analysis by Type of Molecule(s) Involved
10.3.5. Analysis by Type of Service(s) Offered
10.3.6. Analysis by Type of Process(es) Involved
10.3.7. Analysis by Type of Drug Product(s) Involved
10.3.8. Most Active Players: Analysis by Number of Partnerships
10.3.9. Analysis by Geography
10.3.9.1. Intercontinental and Intracontinental Agreements

11. MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Forecast Methodology
11.3. Overall Aseptic Fill Finish Manufacturing Market, 2023-2035
11.3.1. Aseptic Fill Finish Services Market: Analysis by Type of Molecule, 2023-2035
11.3.2. Aseptic Fill Finish Manufacturing Market: Analysis by Type of Packaging Container Offered, 2023-2035
11.3.3. Aseptic Fill Finish Manufacturing Market: Analysis by Type of Drug Product, 2023-2035
11.3.4. Aseptic Fill Finish Manufacturing Market: Analysis by Target Therapeutic Area, 2023-2035
11.3.5. Aseptic Fill Finish Manufacturing Market: Analysis by Scale of Operation, 2023-2035
11.3.6. Aseptic Fill Finish Manufacturing Market: Analysis by Company Size, 2023-2035
11.3.7. Aseptic Fill Finish Manufacturing Market: Analysis by Geography, 2023-2035
11.4. Aseptic Fill Finish Manufacturing Market for Biologics, 2023-2035
11.4.1. Aseptic Fill Finish Manufacturing Market for Biologics: Analysis by Type of Packaging Container Offered, 2023-2035
11.4.2. Aseptic Fill Finish Manufacturing Market: Analysis by Type of Drug Product, 2023-2035
11.4.3. Aseptic Fill Finish Manufacturing Market for Biologics: Analysis by Target Therapeutic Area, 2023-2035
11.4.4. Aseptic Fill Finish Manufacturing Market for Biologics: Analysis by Scale of Operation, 2023-2035
11.4.5. Aseptic Fill Finish Manufacturing Market for Biologics: Analysis by Company Size, 2023-2035
11.4.6. Aseptic Fill Finish Manufacturing Market for Biologics: Analysis by Geography, 2023-2035
11.5. Aseptic Fill Finish Manufacturing Market for Small Molecules, 2023-2035
11.5.1. Aseptic Fill Finish Manufacturing Market for Small Molecules: Analysis by Type of Packaging Container Offered, 2023-2035
11.5.2. Aseptic Fill Finish Manufacturing Market for Small Molecules: Analysis by Scale of Operation, 2023-2035
11.5.3. Aseptic Fill Finish Manufacturing Market for Small Molecules: Analysis by Company Size, 2023-2035
11.5.4. Aseptic Fill Finish Manufacturing Market for Small Molecules: Analysis by Geography, 2023-2035

12. CASE STUDY: ROBOTICS IN PHARMACEUTICAL PACKAGING
12.1. Chapter Overview
12.2. Role of Robotic Systems in Pharmaceutical Industry
12.3. Role of Robotic Systems in Fill / Finish Operation
12.3.1. Types of Robots Used in Pharmaceutical Operations
12.3.2. Advantages Associated with Robotic Systems
12.3.3. Disadvantages Associated with Robotic Systems
12.4.2. Key Considerations for Selecting a Robotic System
12.3. Contract Service Providers: List of Fill Finish Equipment
12.5. Companies Providing Robots for Use in the Pharmaceutical Industry
12.6. Companies Providing Isolator based Aseptic Filling Systems
12.7. Concluding Remarks

13. CASE STUDY: READY-TO-USE PACKAGING COMPONENTS FOR ASEPTIC FILL FINISH
13.1. Chapter Overview
13.2. Role of Ready-to-Use Packaging Components in Aseptic Fill Finish Operations
13.2.1. Advantages of Ready to Use Packaging Components
13.2.2. Disadvantages of Ready to Use Packaging Components
13.3. Companies Providing Ready to Use Packaging Components
13.4. Concluding Remarks

14. CONCLUDING REMARKS

15. EXECUTIVE INSIGHTS
15.1 Chapter Overview
15.2 IDT Biologika
15.2.1. Company Snapshot
15.2.1. Interview Transcript: Gregor Kawaletz, Former Chief Commercial Officer
15.3 Cytovance Biologics
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Matt Delaney, Former Vice President of Business Development and Marketing
15.4. Syngene
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Purushottam Singnurkar, Vice President and Head of Formulation Development
15.5 oncomed manufacturing
15.5.1. Company Snapshot
15.5.2. Interview Transcript: Ales Sima, Head of Business Development
15.6 Yposkesi
15.6.1. Company Snapshot
15.6.2. Interview Transcript: Amit, Former Technology Watch Manager
15.7 HALIX
15.7.1. Company Snapshot
15.7.2. Interview Transcript: Jos Vergeest, International Business Developer

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS